X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (645) 645
Book Review (115) 115
Publication (46) 46
Conference Proceeding (14) 14
Book Chapter (7) 7
Patent (6) 6
Book / eBook (5) 5
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (459) 459
humans (389) 389
oncology (347) 347
male (228) 228
melanoma (216) 216
female (204) 204
middle aged (166) 166
aged (144) 144
cancer (143) 143
adult (133) 133
animals (123) 123
melanoma - pathology (108) 108
melanoma - drug therapy (107) 107
surgery (101) 101
skin neoplasms - pathology (86) 86
prognosis (79) 79
isolated limb perfusion (75) 75
skin neoplasms - drug therapy (72) 72
aged, 80 and over (71) 71
treatment outcome (70) 70
immunology (69) 69
melanoma - mortality (67) 67
immunotherapy (66) 66
neoplasm staging (65) 65
malignant-melanoma (63) 63
tumor necrosis factor-alpha - administration & dosage (63) 63
melphalan (62) 62
rats (62) 62
cutaneous melanoma (61) 61
interferon-gamma (60) 60
melphalan - administration & dosage (60) 60
metastatic melanoma (56) 56
hematology, oncology and palliative medicine (54) 54
survival (53) 53
medicine & public health (52) 52
care and treatment (51) 51
chemotherapy, cancer, regional perfusion (51) 51
disease-free survival (51) 51
tnf-alpha (51) 51
antineoplastic agents - therapeutic use (50) 50
skin neoplasms - mortality (50) 50
metastasis (49) 49
melanoma - surgery (48) 48
chemotherapy (47) 47
sarcoma (47) 47
tumors (46) 46
melanoma - secondary (45) 45
melanoma - therapy (44) 44
review (44) 44
chemotherapy, cancer, regional perfusion - methods (43) 43
mice (43) 43
therapy (43) 43
abridged index medicus (42) 42
tumor-necrosis-factor (42) 42
research (41) 41
survival rate (41) 41
extremities (38) 38
lymphatic metastasis (38) 38
surgical oncology (38) 38
health aspects (37) 37
adjuvant therapy (36) 36
adolescent (36) 36
antineoplastic agents - administration & dosage (36) 36
analysis (35) 35
ipilimumab (34) 34
skin neoplasms - surgery (34) 34
survival analysis (34) 34
combined modality therapy (33) 33
follow-up studies (33) 33
sarcoma - drug therapy (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
interferon-alpha - therapeutic use (31) 31
retrospective studies (31) 31
lymph node excision (30) 30
time factors (30) 30
trial (30) 30
antineoplastic agents, alkylating - administration & dosage (29) 29
chemotherapy, adjuvant (29) 29
high-risk melanoma (29) 29
medicine, research & experimental (29) 29
combination (28) 28
factor-alpha (28) 28
interferon (28) 28
sentinel lymph node biopsy (28) 28
clinical trials (27) 27
metastases (27) 27
pharmacology & pharmacy (27) 27
risk factors (27) 27
biopsy (26) 26
prognostic-factors (26) 26
young adult (26) 26
neoplasm metastasis (25) 25
expression (24) 24
melanoma - immunology (24) 24
skin neoplasms - therapy (24) 24
clinical trials as topic (23) 23
kaplan-meier estimate (23) 23
antibodies, monoclonal - therapeutic use (22) 22
antineoplastic agents - pharmacology (22) 22
breast-cancer (22) 22
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Translational Medicine, ISSN 1479-5876, 12/2019, Volume 17, Issue 1, pp. 1 - 11
The great debate session at the 2018 Melanoma Bridge congress (November 29–December 1, Naples, Italy) featured counterpoint views from experts on three topical... 
Congress | Medical research | Antigens | Melanoma | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Gene expression | Patients | Cancer therapies | Quality of life | Immunotherapy | Drug dosages | BRAF inhibitor | Anti-PD-1 | Targeted therapy | Anti-CTLA-4
Journal Article
Journal Article
by Amaria, Rodabe N and Menzies, Alexander M and Burton, Elizabeth M and Scolyer, Richard A and Tetzlaff, Michael T and Antdbacka, Robert and Ariyan, Charlotte and Bassett, Roland and Carter, Brett and Daud, Adil and Faries, Mark and Fecher, Leslie A and Flaherty, Keith T and Gershenwald, Jeffrey E and Hamid, Omid and Hong, Angela and Kirkwood, John M and Lo, Serigne and Margolin, Kim and Messina, Jane and Postow, Michael A and Rizos, Helen and Ross, Merrick I and Rozeman, Elisa A and Saw, Robyn P M and Sondak, Vernon and Sullivan, Ryan J and Taube, Janis M and Thompson, John F and van de Wiel, Bart A and Eggermont, Alexander M and Davies, Michael A and Andrews, Miles C and Berry, Donald A and Block, Matthew S and Boland, Genevieve M and Bollin, Kathryn B and Carlino, Matteo S and Carvajal, Richard D and Cohen, Jonathan and Davar, Diwakar and Delman, Keith A and Dummer, Reinhard and Farwell, Michael D and Fisher, David E and Fusi, Alberto and Glitza, Isabella C and de Gruijl, Tanja D and Gyorki, David E and Hauschild, Axel and Hieken, Tina J and Larkin, James and Lawson, David H and Lebbe, Celeste and Lee, Jeffrey E and Lowe, Michael C and Luke, Jason J and McArthur, Grant A and McDermott, David F and McQuade, Jennifer L and Mitchell, Tara C and Petrella, Teresa M and Prieto, Peter A and Puzanov, Igor and Robert, Caroline and Salama, April K and Sandhu, Shaneen and Schadendorf, Dirk and Shoushtari, Alexander N and Sosman, Jeffrey A and Swetter, Susan M and Tanabe, Ken K and Turajlic, Samra and Tyler, Douglas S and Woodman, Scott E and Wright, Frances C and Zager, Jonathan S and Ascierto, Paolo A and Spillane, Andrew J and van Akkooi, Alexander C J and Wargo, Jennifer A and Blank, Christian U and Tawbi, Hussein A and Long, Georgina V and Int Neoadjuvant Melanoma
The Lancet Oncology, ISSN 1470-2045, 07/2019, Volume 20, Issue 7, pp. e378 - e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to... 
SURVIVAL | PREOPERATIVE CHEMOTHERAPY | RESPONSE CRITERIA | ONCOLOGY | IMMUNOTHERAPY | TRAMETINIB | ADJUVANT DABRAFENIB | DISEASE | GUIDELINES | STAGE-III | BREAST | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Melanoma | Cancer
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 7/2019, Volume 68, Issue 7, pp. 1171 - 1178
Immune checkpoint inhibitors are now standard-of-care treatments for metastatic cutaneous melanoma. However, for rare sub-groups, such as mucosal melanomas,... 
Pembrolizumab | Immunology | Medicine & Public Health | Immunotherapy | Ipilimumab | Anti-CTLA4 | Oncology | Cancer Research | Anti-PD1 | Mucosal melanoma | SURVIVAL | SAFETY | CHOICE CHEMOTHERAPY | COMBINED NIVOLUMAB | OPEN-LABEL | IMMUNOLOGY | CHECKMATE 037 | ONCOLOGY | UVEAL | ANTI-PD-1 | Metastasis | Drug therapy | Health aspects | Analysis | Melanoma | CTLA-4 protein | Mucosal immunity | Immune checkpoint | Rectum | Vagina | Head and neck | Tumors | Metastases | Index Medicus
Journal Article
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 05/2019, Volume 17, Issue 1, pp. 148 - 148
The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical... 
Anti-PD-1 | Targeted therapy | Anti-CTLA-4 | Immunotherapy | Melanoma | BRAF inhibitor | Neoadjuvant | Adjuvant | MEK inhibitor | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | STAGE-III | METASTATIC MELANOMA | THERAPIES | NIVOLUMAB | IPILIMUMAB | PROGRESSION | Antimitotic agents | Antineoplastic agents
Journal Article
Molecular Oncology, ISSN 1574-7891, 03/2019, Volume 13, Issue 3, pp. 497 - 501
Journal Article
Molecular Oncology, ISSN 1574-7891, 03/2019, Volume 13, Issue 3, pp. 521 - 527
Cancer Core Europe is a European legal alliance consisting of seven leading cancer centres – most of them Comprehensive Cancer Centres ( CCC s) – with a single... 
innovation | oncopolicy | alliance | infrastructure | cancer research | CONSORTIUM | COST | ONCOLOGY | BURDEN | UNION | CARE | Review
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2019, Volume 120, Issue 1, pp. 3 - 5
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of... 
MULTICENTER | PEMBROLIZUMAB | ONCOLOGY | SAFETY | OPEN-LABEL | NIVOLUMAB | DOCETAXEL | Medical research | Sensitivity | PD-1 protein | Immunotherapy | PD-L1 protein | Clinical trials | Subgroups | Cancer | Index Medicus
Journal Article
by Visigalli, I and Cecere, F and Carriglio, N and Hernandez, R J and Hernandez, R J and De Simone, M and Vezzoli, M and Monti, L and Zino, E and Alfonso, E and Sanvito, F and Mauro, V and Norata, R and Acquati, S and Acquati, S and Redaelli, D and Redaelli, D and Dionisio, F and De Mattia, F and Scaramuzza, S and Rossi, C and Giannelli, S and Giannelli, S and Salerio, F and Sartirana, C and Brigida, I and Magni, S and Miglietta, S and Monteverde, S and Monti, I and Gregori, S and Ferrari, G and Aiuti, A and Castagnaro, L and Zancan, S and Cristofori, P and Naldini, L and Bonini, C and Waselle, L and Tissot, L and Sitjve, S and Büning, H and Ayuso, E and Déglon, N and Bueren, J and Trono, D and Nobrega, C and Mendonça, L and Marcelo, A and Lamazière, A and Tomé, S and Tomé, S and Déspres, G and Matos, C and Mechmet, F and Langui, D and den Dunnen, W and Pereira de Almeida, L and Cartier, N and Mitchell, J and Nemesh, J and Ghosh, S and Mello, C and McCaroll, S and Di Pasquale, G and Chandler, R J and Choi, E Y and Hubbard, B and Afione, S and Khalaj, M and Zheng, C and Grewe, B and Kaler, S G and Venditti, C P and Grimm, D and Grimm, D and Buj Bello, A and Nyns, E CA and Bingen, B O and Bart, C I and Kip, A and Poelma, R H and Volkers, L and Plomp, J J and Jangsangthong, W and Engels, M C and Schalij, M J and Zhang, G Q and Pijnappels, D A and Hildebrant, E and Penzes, J and Agbandje-McKenna, M and Gifford, R and Xiao, X and Akcakaya, P and Bobbin, M L and Guo, J A and Malagon-Lopez, J and Clement, K and Garcia, S P and ...
Human Gene Therapy, ISSN 1043-0342, 12/2018, Volume 29, Issue 12, pp. A1 - A169
Journal Article
Nature Medicine, ISSN 1078-8956, 12/2018, Volume 24, Issue 12, pp. 1877 - 1886
Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and... 
MEDICINE, RESEARCH & EXPERIMENTAL | RNA HELICASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | SENSITIVITY | BRAF | MICE LACKING | CELL BIOLOGY | ONCOGENIC RAS | RESISTANCE | PD-L1 | EIF4F | INHIBITOR | INITIATION COMPLEX | Tumor Escape - drug effects | Protein Biosynthesis | Humans | B7-H1 Antigen - therapeutic use | Eukaryotic Initiation Factor-4F - genetics | Gene Expression Regulation, Neoplastic - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Melanoma - pathology | STAT1 Transcription Factor - genetics | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Animals | B7-H1 Antigen - antagonists & inhibitors | Signal Transduction - drug effects | Melanoma - genetics | Melanoma - immunology | Immunotherapy | Interferon-gamma - immunology | Cell Line, Tumor | Mice | Programmed Cell Death 1 Receptor - therapeutic use | Interferon-gamma - genetics | Melanoma - therapy | Tumor Escape - immunology | Prevention | Usage | Care and treatment | Analysis | Oncology, Experimental | Melanoma | Research | Biological response modifiers | Apoptosis | Cancer | RNA | Interferon | T cells | Genetic translation | Complex formation | PD-1 protein | Drug development | Immunosuppressive agents | Anticancer properties | DNA helicase | Antitumor agents | Bioindicators | Stat1 protein | Initiation complex | Translation | Tumor cells | Translation initiation | Pharmacology | Ribonucleic acid--RNA | Immune checkpoint | PD-L1 protein | Biomarkers | Antitumor activity | RNA helicase | Tumors | Index Medicus
Journal Article